extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
be04ae7054
commit
bcd38c2925
5 changed files with 66 additions and 1 deletions
|
|
@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
|
|||
|
||||
MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's November 2025 Medicare deal establishes $245/month pricing for semaglutide and tirzepatide (82% below list price) with narrow eligibility criteria requiring comorbidities, not just obesity. This dramatically changes the economics analyzed in the original claim: the 'inflationary through 2035' conclusion assumed higher prices (~$1,000+/month) and potentially broader population coverage. The narrow targeting (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD) limits the eligible Medicare population to ~10% of beneficiaries — those where downstream savings are most likely. Under MA capitation, this targeted approach may actually be cost-effective at the plan level even if system-level impact remains inflationary.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence in the Medicare population. The existing claim about 15% two-year persistence was driven partly by affordability — the Trump deal's dramatic cost reduction ($50 OOP vs. previous $1,000+/month) may improve persistence rates specifically in the Medicare population, though this remains to be tested.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's Medicare deal establishes $50/month out-of-pocket maximum for beneficiaries, explicitly targeting affordability as a persistence barrier. The deal structure (manufacturer concessions to achieve low OOP costs) confirms that policymakers recognize affordability as a primary driver of discontinuation, not just clinical factors.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:set_created:2026-03-16",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:missing_attribution_extractor",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-11-06
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: news
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,14 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
|
||||
EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare GLP-1 payment demonstration begins July 2026
|
||||
- BALANCE Model in Medicaid launches May 2026
|
||||
- BALANCE Model in Medicare Part D begins January 2027
|
||||
- Oral Wegovy launches January 2026 at $149-$299/month
|
||||
- Estimated 10% of Medicare beneficiaries eligible under the narrow criteria
|
||||
- Medicare/Medicaid price: $245/month for semaglutide and tirzepatide
|
||||
- TrumpRx general price: $350/month (down from ~$1,350/month injectable)
|
||||
- Medicare beneficiary OOP maximum: $50/month for tirzepatide starting April 2026
|
||||
|
|
|
|||
Loading…
Reference in a new issue